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2013;309:896–908.Letter to the Editor— When to implant an ICD following a
myocardial infarction?
Hess et al1 conclude that there does not seem to be any
evidence suggesting that the efﬁcacy of primary prevention
implantable cardioverter-deﬁbrillator (ICD) therapy depends
on time to implantation 440 days after myocardial infarc-
tion (MI). Their ﬁndings were based on the results of 4
primary prevention ICD trials—Multicenter Automatic Deﬁ-
brillator Implantation Trial (MADIT-I), Multicenter Unsus-
tained Tachycardia Trial (MUSTT), MADIT-II, and Sudden
Cardiac Death in Heart Failure Trial (SCD-HeFT)—and may
support our current understanding of who is the best
candidate for an ICD.
Although a previous post hoc analysis of the SCD-HeFT
trial shared the same results,2 our interpretation of the present
meta-analysis data is slightly different. In fact, hazard ratios
obtained using the adjusted BayesianWeibull survival model
indicate a potential interaction between time fromMI and all-
cause mortality, as those implanted with an ICD 1–5 years
after MI seemed to fare better. This is in accord with data
from MADIT-II and SCD-HeFT, in which beneﬁt of the ICD
in the primary prevention of sudden cardiac death emerged
only in a mid- to long-term follow-up (2–5 years).3
Randomized controlled trials are not usually representative
of the whole population as they tend to exclude patients
deemed to have a poorer prognosis. For example, MADIT-II
excluded “all patients with any condition other than cardiac
disease that could associate with high likelihood of death
during the trial.” Furthermore, patients with higher comorbidity
burden tend to be unconsciously excluded even when fulﬁlling
inclusion criteria. These patients are at higher arrhythmic and
especially nonarrhythmic mortality risk and probably do not
get the same survival beneﬁt from an ICD compared to their
“healthier” counterparts. For example, in a post hoc subana-
lysis of patients fromMADIT-II, there was no difference in the
2-year mortality rates for patients with an estimated glomerular
ﬁltration rate o35 mL/(min  1.73 m2) randomized to an ICD
or conventional treatment.4 Natural selection implies that those
surviving the ﬁrst year after MI are at a relatively lower
nonarrhythmic mortality risk and may have a lower comorbid-
ity burden and thus a longer life expectancy; therefore, they
could potentially beneﬁt from an ICD. Hence, in addition to the
current controversy regarding the potential beneﬁt, or lack
thereof, of an ICD in patients with multiple markers of organ
dysfunction,5 the best timing for its implantation in this cohort
remains mostly unknown. We speculate that in the range of
patients covered by the guidelines, the healthier the patients themore likely they are to either get no beneﬁt from an ICD or
need several years to start beneﬁting. A study by Goldenberg
et al6 seems to support this thesis, as patients without risk
factors such as New York Heart Association class higher than
II, age 470 years, urea level 426 mg/dL, QRS duration
4120 ms, and atrial ﬁbrillation did not get any beneﬁt from the
ICD. On the contrary, supposedly sicker individuals (eg, those
with multiorgan dysfunction) are not expected to get much
beneﬁt in the ﬁrst year after MI, as they tend to die from
nonarrhythmic causes but may eventually be good candidates
if they survive the ﬁrst year.
Patients from MADIT-I and MUSTT were the ones
beneﬁting the most from an ICD implantation in the ﬁrst 6
months, which may suggest that the electrophysiological study
might be useful for identifying those entitled to an early ICD,
although routine performance of an electrophysiological study
in these patients is not currently recommended.
Finally, we wonder whether an ICD programming in the 4
trials similar to that of the MADIT-Reduce Inappropriate
Therapy study could potentially improve overall survival,
decrease the high incidence of inappropriate shocks, and
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